The White House budget
proposal, released earlier this month, includes a requirement for
pharmaceutical companies to disclose various business measures, including the
cost of research and development; a requirement that would either prove or lay
to rest to pharma’s continued argument that drug prices are directly related to
their R&D costs. The measures mimic those proposed by states across the
country and received similar backlash from industry lobbyists – including
assertions that the requirement would stifle innovation, ignores R&D
failures, and requires the disclosure of confidential information. That final
argument is likely countered by an existing statute in the Affordable Care Act.
Read the coverage from Pharmalot's Ed Silverman here.
No comments:
Post a Comment